Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients

Shun-Ichiro Kageyama; Keiji Nihei; Katsuyuki Karasawa; Takeshi Sawada; Fumiaki Koizumi; Shigeo Yamaguchi; Shunsuke Kato; Hidehiro Hojo; Atsuhi Motegi; Katsuya Tsuchihara; Tetsuo Akimoto

doi:10.18632/oncotarget.25053

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:23844.

Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients

Shun-Ichiro Kageyama _, Keiji Nihei, Katsuyuki Karasawa, Takeshi Sawada, Fumiaki Koizumi, Shigeo Yamaguchi, Shunsuke Kato, Hidehiro Hojo, Atsuhi Motegi, Katsuya Tsuchihara and Tetsuo Akimoto

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:19368-19378. https://doi.org/10.18632/oncotarget.25053

Metrics: PDF 2603 views | HTML 2397 views | ?

Abstract

Shun-ichiro Kageyama1, Keiji Nihei1, Katsuyuki Karasawa1, Takeshi Sawada1, Fumiaki Koizumi1, Shigeo Yamaguchi1, Shunsuke Kato1, Hidehiro Hojo1, Atsuhi Motegi1, Katsuya Tsuchihara1 and Tetsuo Akimoto1

1National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan

Correspondence to:

Shun-ichiro Kageyama, email: [email protected]

Keywords: tumoral cell-free DNA; radiotherapy; NSCLC; tumor-specific mutations; digital PCR

Received: November 21, 2017 Accepted: March 21, 2018 Published: April 10, 2018

ABSTRACT

We investigated the plasma levels of tumor-specific cell-free DNA (cfDNA) in 17 stage I–II (early) and IV (advanced) non-small cell lung cancer (NSCLC) patients who underwent radiotherapy. Digital polymerase chain reaction (PCR) and targeted sequencing showed that total and tumor-specific cfDNA levels increased in response to radiotherapy in both early- and advanced-stage NSCLC patients. We detected high copy numbers of epidermal growth factor receptor mutations (L858R and T790M) in the cfDNA samples from stage IV NSCLC patients who underwent stereotactic body radiation therapy to treat brain metastasis related to tyrosine kinase inhibitor (TKI) treatment failure. In conclusion, our study demonstrates that radiotherapy increases tumoral cfDNA levels in the plasma and shows potential to serve as an indicator for diagnosing drug-resistant tumor-related gene mutations in early-stage NSCLC patients or those undergoing molecular targeted therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25053

Publication Alerts

Research Papers:

Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients

Abstract